ANXA2P2: A Potential Immunological and Prognostic Signature in Ovarian Serous Cystadenocarcinoma
ANXA2P2
immune characteristics
ovarian serous cystadenocarcinoma
prognostic signature
pseudogene
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
20
11
2021
accepted:
10
01
2022
entrez:
25
2
2022
pubmed:
26
2
2022
medline:
26
2
2022
Statut:
epublish
Résumé
Although the effect of pseudogene ANXA2P2 on some tumors has been reported in a few literatures, the therapeutic potential and prognostic value of ANXA2P2 in ovarian serous cystadenocarcinoma (OV) have not been elucidated. The correlation for ANXA2P2 expression patterns to prognostic characteristics, tumor immune microenvironment, immune cell infiltration level, tumor mutation burden (TMB), tumor microsatellite instability (MSI), drug sensitivity, and pathway function enrichment were investigated in pan-carcinoma ANXA2P2 was frequently overexpressed in a variety of tumors compared with normal tissues. The correlation analysis for prognostic characteristics, tumor immune microenvironment, immune cell infiltration level, TMB, MSI, drug sensitivity, and pathway function enrichment revealed that ANXA2P2 expression patterns might deal a significant impact on the pathogenesis, development, and prognosis of various tumors. Then, GSVA, GSEA, WGCNA, gene mutation, and independent prognostic analysis for OV have indicated that high expression in ANXA2P2 could be mostly enriched in TNF-α signaling- In summary, our findings might provide a helpful foundation for prospective explorative researches, afford new strategies for the clinical treatment, deal prognosis prediction, and give new hope for OV patients.
Sections du résumé
BACKGROUND
BACKGROUND
Although the effect of pseudogene ANXA2P2 on some tumors has been reported in a few literatures, the therapeutic potential and prognostic value of ANXA2P2 in ovarian serous cystadenocarcinoma (OV) have not been elucidated.
METHODS
METHODS
The correlation for ANXA2P2 expression patterns to prognostic characteristics, tumor immune microenvironment, immune cell infiltration level, tumor mutation burden (TMB), tumor microsatellite instability (MSI), drug sensitivity, and pathway function enrichment were investigated in pan-carcinoma
RESULTS
RESULTS
ANXA2P2 was frequently overexpressed in a variety of tumors compared with normal tissues. The correlation analysis for prognostic characteristics, tumor immune microenvironment, immune cell infiltration level, TMB, MSI, drug sensitivity, and pathway function enrichment revealed that ANXA2P2 expression patterns might deal a significant impact on the pathogenesis, development, and prognosis of various tumors. Then, GSVA, GSEA, WGCNA, gene mutation, and independent prognostic analysis for OV have indicated that high expression in ANXA2P2 could be mostly enriched in TNF-α signaling-
CONCLUSION
CONCLUSIONS
In summary, our findings might provide a helpful foundation for prospective explorative researches, afford new strategies for the clinical treatment, deal prognosis prediction, and give new hope for OV patients.
Identifiants
pubmed: 35211410
doi: 10.3389/fonc.2022.818977
pmc: PMC8860902
doi:
Types de publication
Journal Article
Langues
eng
Pagination
818977Informations de copyright
Copyright © 2022 Zhang, Du and Chen.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Genome Biol. 2021 Aug 23;22(1):240
pubmed: 34425866
Int J Cancer. 2019 May 1;144(9):2074-2081
pubmed: 30125343
J Intern Med. 2021 Jan;289(1):12-28
pubmed: 32656940
Methods Mol Biol. 2021;2324:319-337
pubmed: 34165724
Cell Death Dis. 2021 Mar 12;12(3):261
pubmed: 33712571
Exp Mol Pathol. 2006 Oct;81(2):146-56
pubmed: 16643892
Int J Gynecol Cancer. 2020 Nov;30(11):1803-1810
pubmed: 32895312
Cancer Res. 2012 Jul 15;72(14):3499-511
pubmed: 22802077
Blood. 2012 Aug 2;120(5):1087-94
pubmed: 22705595
Cancer. 2013 Jan 15;119(2):332-8
pubmed: 22811390
Lung Cancer. 2019 Apr;130:50-58
pubmed: 30885352
Genes Dis. 2017 Nov 21;5(1):27-35
pubmed: 30258932
Front Genet. 2016 Mar 24;7:26
pubmed: 27047535
Ann Oncol. 2019 Aug 1;30(8):1232-1243
pubmed: 31056702
Molecules. 2020 Nov 20;25(22):
pubmed: 33233619
Eur J Cancer. 2020 May;131:40-50
pubmed: 32278982
Nat Rev Genet. 2020 Mar;21(3):191-201
pubmed: 31848477
Gastroenterology. 2011 Feb;140(2):583-595.e4
pubmed: 20826156
Nucleic Acids Res. 2009 Jan;37(Database issue):D738-43
pubmed: 18957444
Ann Oncol. 2017 Nov 1;28(suppl_8):viii1-viii7
pubmed: 29232467
J Biochem Mol Toxicol. 2021 Sep;35(9):e22838
pubmed: 34273909
J Exp Clin Cancer Res. 2021 Jun 24;40(1):209
pubmed: 34167551
Nat Commun. 2014 Jul 07;5:3963
pubmed: 24999802
Dis Markers. 2019 Feb 10;2019:9267046
pubmed: 30881525
Eur J Cancer. 2021 Jun;150:155-167
pubmed: 33901794
JCO Precis Oncol. 2017;2017:
pubmed: 29850653
Int J Hematol. 2009 Sep;90(2):177-185
pubmed: 19585213
Gene. 2002 May 1;289(1-2):185-90
pubmed: 12036597
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Biol Chem. 2004 Mar 5;279(10):8723-31
pubmed: 14672933
Cell. 2012 Jun 22;149(7):1622-34
pubmed: 22726445
Front Oncol. 2019 Oct 15;9:1059
pubmed: 31681595
J Neurosci. 2011 Oct 5;31(40):14346-60
pubmed: 21976520
Urol Oncol. 2015 Jan;33(1):22.e11-22.e21
pubmed: 25284003
J Control Release. 2014 Jun 28;184:67-78
pubmed: 24727000
J Biochem Mol Toxicol. 2021 Aug;35(8):e22824
pubmed: 34047431
BMC Cancer. 2021 Mar 16;21(1):282
pubmed: 33726687
J Clin Oncol. 2018 Oct 20;36(30):2978-2979
pubmed: 30179566
Blood. 2012 Feb 23;119(8):1888-96
pubmed: 22223826
Bioinformatics. 2019 Oct 15;35(20):4200-4202
pubmed: 30903160
Gut. 2004 Jul;53(7):993-1000
pubmed: 15194650
Biochim Biophys Acta Biomembr. 2020 Sep 1;1862(9):183278
pubmed: 32240623
Cancer Sci. 2019 Dec;110(12):3622-3629
pubmed: 31594033
Cancer. 2020 May 15;126(10):2225-2249
pubmed: 32162336
Methods Mol Biol. 2021;2324:3-18
pubmed: 34165705
Mol Cancer. 2015 Aug 15;14:156
pubmed: 26272794
Int J Oncol. 2008 Dec;33(6):1157-63
pubmed: 19020748
J Clin Oncol. 2018 Mar 1;36(7):631-632
pubmed: 29337637
Nat Genet. 2003 Jul;34(3):267-73
pubmed: 12808457
Cell Signal. 2020 Oct;74:109718
pubmed: 32707073
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Nat Rev Clin Oncol. 2019 Jul;16(7):403
pubmed: 30874612
BMC Bioinformatics. 2013 Jan 16;14:7
pubmed: 23323831
JAMA Oncol. 2018 Feb 1;4(2):190-195
pubmed: 29222541
Stem Cells. 2013 Jul;31(7):1383-95
pubmed: 23553791
Nat Rev Cancer. 2017 Jan;17(1):65-74
pubmed: 27885265
Methods Mol Biol. 2021;2324:131-147
pubmed: 34165713
Lancet Oncol. 2018 Sep;19(9):e446
pubmed: 30122616
BMC Genomics. 2009 Jun 23;10:277
pubmed: 19549304
Front Genet. 2014 Jul 03;5:194
pubmed: 25071824
Genes Chromosomes Cancer. 2018 Jul;57(7):366-376
pubmed: 29575536
Lancet Digit Health. 2021 Oct;3(10):e654-e664
pubmed: 34417147
Ann Oncol. 2016 Apr;27 Suppl 1:i16-i19
pubmed: 27141064
Cancer Cell. 2020 Sep 14;38(3):412-423.e9
pubmed: 32679107